Krystal Biotech Income Statement (2021-2026) | KRYS

Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
8.56M42.14M45.30M70.28M83.80M91.11M88.18M96.00M97.80M107.08M116.36M
Cost of Revenue (Quarter)
0.22M2.87M2.42M6.01M6.68M4.95M5.03M7.17M4.26M6.59M6.32M
Gross Profit (Quarter)
8.33M39.27M42.88M64.28M77.12M86.17M83.16M88.83M93.54M100.48M110.03M
Operating items
Research & Development (Quarter)
6.59M6.08M9.01M9.31M10.89M11.52M10.74M12.29M12.14M10.63M11.37M10.96M15.58M13.51M13.53M14.26M14.41M14.59M14.79M15.33M
Selling, General & Administrative (Quarter)
9.80M9.57M12.87M15.91M17.86M19.93M24.03M24.04M25.90M23.70M24.65M26.06M27.63M28.67M31.29M32.72M35.16M37.58M41.45M41.01M
Restructuring Costs (Quarter)
25.00M12.50M12.50M37.50M12.50M37.50M12.50M
Other Operating Expenses (Quarter)
-12.50M100.00M2.42M-18.99M5.03M7.17M4.26M6.59M6.32M
Operating Expenses (Quarter)
16.39M15.65M21.88M50.22M28.75M31.45M34.77M48.82M38.05M34.55M38.90M51.93M61.72M61.37M49.76M52.01M56.73M56.43M62.84M62.67M
Operating Income (Quarter)
-16.39M-15.65M-21.88M-50.22M-28.75M-31.45M-34.77M-48.82M-38.05M-25.99M3.25M-6.68M8.57M22.47M41.38M36.18M39.31M41.37M44.27M53.69M
EBIT (Quarter)
-16.39M-15.65M-21.88M-50.22M-28.75M-31.45M-34.77M-48.82M-38.05M-25.99M3.25M-6.68M8.57M22.47M41.38M36.18M39.31M41.37M44.27M53.69M
Non-operating items
Interest & Investment Income (Quarter)
0.03M0.06M0.07M0.26M0.65M1.60M2.72M3.53M4.84M6.74M7.41M7.62M7.48M7.30M7.24M7.42M7.47M6.59M6.86M7.75M
Net income details
EBT (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M10.66M0.93M16.05M29.77M48.61M43.60M46.77M47.97M51.13M61.44M
Tax Provisions (Quarter)
1.97M0.48M2.60M3.10M7.86M8.44M-31.40M-0.26M5.51M
Profit After Tax (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.18M45.48M35.73M38.33M79.36M51.40M55.93M
Income from Continuing Operations (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.17M45.51M35.73M38.33M79.37M51.39M55.93M
Consolidated Net Income (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.17M45.51M35.73M38.33M79.37M51.39M55.93M
Income towards Parent Company (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.17M45.51M35.73M38.33M79.37M51.39M55.93M
Net Income towards Common Stockholders (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.17M45.51M35.73M38.33M79.37M51.39M55.93M
Additional items
EPS (Basic) (Quarter)
-0.74-0.70-0.95-1.99-1.10-1.17-1.25-1.76-1.252.880.320.030.540.951.591.241.332.741.771.91
EPS (Weighted Average and Diluted) (Quarter)
-0.74-0.70-0.95-1.99-1.10-1.17-1.25-1.76-1.252.790.310.030.530.911.531.201.292.661.701.83
Shares Outstanding (Weighted Average) (Quarter)
22.20M21.89M22.20M25.11M25.55M25.43M25.49M25.71M26.19M26.81M27.15M28.30M28.45M28.72M28.59M28.82M28.91M28.95M28.94M29.29M
Shares Outstanding (Diluted Average) (Quarter)
21.73M22.21M22.20M25.11M25.55M25.43M25.49M25.71M26.19M27.39M27.75M29.29M29.64M29.67M29.74M29.87M29.82M29.83M29.95M30.51M
EBITDA (Quarter)
-16.39M-15.58M-21.95M-51.00M-28.46M-29.78M-31.30M-44.72M-33.29M80.60M9.71M-0.01M15.23M29.33M43.78M36.31M39.10M79.31M51.44M53.17M
Interest Expenses (Quarter)
Tax Rate (Quarter)
18.44%2.97%8.73%6.37%18.04%18.05%-65.46%-0.51%8.97%